CY1119800T1 - Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων - Google Patents

Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων

Info

Publication number
CY1119800T1
CY1119800T1 CY20181100069T CY181100069T CY1119800T1 CY 1119800 T1 CY1119800 T1 CY 1119800T1 CY 20181100069 T CY20181100069 T CY 20181100069T CY 181100069 T CY181100069 T CY 181100069T CY 1119800 T1 CY1119800 T1 CY 1119800T1
Authority
CY
Cyprus
Prior art keywords
inhibitors
acthylcholinesteration
concentrators
connectors
cognitive disorder
Prior art date
Application number
CY20181100069T
Other languages
Greek (el)
English (en)
Inventor
David Beattie
Fei Shen
Jacqueline A. M. Smith
Robert Murray Mckinnell
Ray Chang
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of CY1119800T1 publication Critical patent/CY1119800T1/el

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/468-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY20181100069T 2009-04-13 2018-01-19 Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων CY1119800T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16874109P 2009-04-13 2009-04-13
US29255910P 2010-01-06 2010-01-06
PCT/US2010/030760 WO2010120695A2 (en) 2009-04-13 2010-04-12 5-ht4 receptor agonist compounds for treatment of cognitive disorders

Publications (1)

Publication Number Publication Date
CY1119800T1 true CY1119800T1 (el) 2018-06-27

Family

ID=42237213

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20181100069T CY1119800T1 (el) 2009-04-13 2018-01-19 Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων

Country Status (24)

Country Link
US (2) US8404711B2 (enExample)
EP (1) EP2419104B1 (enExample)
JP (1) JP2012523437A (enExample)
KR (1) KR20120017421A (enExample)
CN (2) CN102395371A (enExample)
AU (1) AU2010236734B2 (enExample)
BR (1) BRPI1013777A8 (enExample)
CA (1) CA2758321A1 (enExample)
CY (1) CY1119800T1 (enExample)
DK (1) DK2419104T3 (enExample)
ES (1) ES2654930T3 (enExample)
HR (1) HRP20180018T1 (enExample)
HU (1) HUE038141T2 (enExample)
IL (1) IL215660A0 (enExample)
LT (1) LT2419104T (enExample)
MX (1) MX2011010782A (enExample)
NO (1) NO2419104T3 (enExample)
PL (1) PL2419104T3 (enExample)
PT (1) PT2419104T (enExample)
RU (1) RU2569056C2 (enExample)
SI (1) SI2419104T1 (enExample)
SM (1) SMT201800036T1 (enExample)
WO (1) WO2010120695A2 (enExample)
ZA (1) ZA201107490B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
MY173229A (en) 2008-11-19 2020-01-07 Forum Pharmaceuticals Inc Treatment of cognitive disorders with (r)-7-chloro-n-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
RU2011150248A (ru) * 2009-05-11 2013-06-20 Энвиво Фармасьютикалз, Инк. Лечение когнитивных расстройств с определенными рецепторами альфа-7 никотиновой кислоты в комбинации с ингибиторами ацетилхолинэстеразы
PT3029039T (pt) 2010-05-17 2017-11-28 Forum Pharmaceuticals Inc Formulações farmacêuticas que compreendem formas cristalinas de cloridrato de (r)-7-cloro-n-(quinuclidin-3-il)benzo(b)tiofeno-2-carboxamida mono-hidratado
EP2846796A4 (en) 2012-05-08 2015-10-21 Forum Pharmaceuticals Inc METHODS OF MAINTAINING, PROCESSING OR ENHANCING COGNITIVE FUNCTION
US20150306158A1 (en) 2012-08-16 2015-10-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
US10874701B2 (en) 2012-08-16 2020-12-29 University-Industry Cooperation Group Of Kyung Hee University Lactic acid bacteria capable of preventing and/or treating senescence and dementia
SMT202100240T1 (it) 2017-05-24 2021-05-07 H Lundbeck As Combinazione di un antagonista del recettore di 5-ht6 e un inibitore della acetilcolinesterasi per l'uso nel trattamento della malattia di alzheimer in una sottopopolazione di pazienti portatori di alleli apoe4
KR20200010211A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
SG11201911512SA (en) 2017-06-02 2020-01-30 Fujifilm Toyama Chemical Co Ltd Agent for preventing or treating brain atrophy
PT3661518T (pt) 2017-07-31 2024-11-04 Alfasigma Spa Métodos de tratamento dos sintomas da gastroparesia usando velusetrag

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE345803T1 (de) * 2000-03-03 2006-12-15 Eisai Co Ltd Neue methoden unter verwendung von cholinesteraseinhibitoren
TWI351282B (en) * 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
TWI377206B (en) * 2005-04-06 2012-11-21 Theravance Inc Crystalline form of a quinolinone-carboxamide compound
MY147756A (en) * 2005-05-25 2013-01-15 Theravance Inc Benzimidazole-carboxamide compounds as 5-ht4 receptor agonists

Also Published As

Publication number Publication date
CN102395371A (zh) 2012-03-28
IL215660A0 (en) 2012-01-31
US20100261752A1 (en) 2010-10-14
CA2758321A1 (en) 2010-10-21
WO2010120695A2 (en) 2010-10-21
NO2419104T3 (enExample) 2018-04-07
KR20120017421A (ko) 2012-02-28
RU2569056C2 (ru) 2015-11-20
EP2419104B1 (en) 2017-11-08
DK2419104T3 (en) 2018-02-05
CN105832735A (zh) 2016-08-10
BRPI1013777A2 (pt) 2016-04-05
SMT201800036T1 (it) 2018-03-08
ES2654930T3 (es) 2018-02-15
WO2010120695A3 (en) 2010-12-02
HUE038141T2 (hu) 2018-10-29
RU2011146032A (ru) 2013-05-20
ZA201107490B (en) 2012-06-27
SI2419104T1 (en) 2018-03-30
LT2419104T (lt) 2018-02-12
AU2010236734B2 (en) 2015-06-11
EP2419104A2 (en) 2012-02-22
AU2010236734A1 (en) 2011-11-03
MX2011010782A (es) 2012-01-20
PL2419104T3 (pl) 2018-04-30
PT2419104T (pt) 2018-01-31
US20140057939A1 (en) 2014-02-27
US8404711B2 (en) 2013-03-26
BRPI1013777A8 (pt) 2017-09-19
AU2010236734A8 (en) 2012-02-16
JP2012523437A (ja) 2012-10-04
HRP20180018T1 (hr) 2018-02-09

Similar Documents

Publication Publication Date Title
CY1119800T1 (el) Συνδυασμοι υποδοχεα της 5-ητ4 και αναστολεων ακετυλοχολινεστερασης για τη θεραπεια γνωστικων διαταραχων
CY1125436T1 (el) Αναστολεις dna-pk
CY1119057T1 (el) Συνδετες υποδοχεα οπιοειδους και μεθοδοι χρησης και κατασκευης αυτων
CY1121695T1 (el) Ενωσεις και συνθεσεις ως αναστολεις κινασης c-kit
CY1121065T1 (el) Αναστολεις ιβατ για την αγωγη ηπατικων νοσων
CY1123051T1 (el) Ταπενταδολη για προληψη και θεραπεια καταθλιψης και αγχους
CY1120102T1 (el) Συνθεσεις και μεθοδοι για μειωση τριγλυκεριδιων χωρις αυξηση επιπεδων ldl-c σε ενα υποκειμενο επι ταυτοχρονης θεραπειας στατινης
EA201101009A1 (ru) АНТАГОНИСТЫ C5aR
EA201100062A1 (ru) Соединения и способы модулирования рецепторов, связанных с белком g
MA32547B1 (fr) Antagonistes specifiques du recepteur fgf-r4
EA200970737A1 (ru) Оксабициклогептаны и оксабициклогептены, их получение и применение
CY1114872T1 (el) Συνθεσεις και μεθοδοι χρησης αντισωματων εναντι της σκληροστεϊνης
CY1113640T1 (el) Μεθοδοι για την θεραπευτικη αγωγη ρευματοειδους αρθριτιδας
CY1113980T1 (el) Νεες θεραπευτικες μεθοδευσεις για θεραπευτικη αγωγη cmt και συναφων διαταραχων
ME01532B (me) Jedinjenja
EA201171367A1 (ru) Винилиндазолильные соединения
EA201071248A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
EA201170227A1 (ru) Имидазолкарбоксамиды
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
CY1115975T1 (el) Ταπενταδολη για τη θεραπεια πονου σε αρθριτιδα
EA201171063A1 (ru) Фармацевтические составы олмесартана
CY1115437T1 (el) Υδροξυμεθυλοκυκλοεξυλαμινες
CY1116802T1 (el) Ετεροκυκλικες ενωσεις
EA201390977A1 (ru) Комбинация агониста опиоидных рецепторов и антагониста опиоидных рецепторов для лечения болезни паркинсона
MY147649A (en) Benzimidazole derivatives useful in treatment of vallinoid receptor trpv1 related disorders